A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05830097. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.
Study identification
- NCT ID
- NCT05830097
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 260 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 13, 2023
- Primary completion
- Jun 29, 2025
- Completion
- Sep 29, 2025
- Last update posted
- Aug 25, 2024
2023 – 2025
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TOI Clinical Research LLC | Cerritos | California | 90805 | Recruiting |
| Florida Cancer Specialists & Research Institute | Orlando | Florida | 32827 | Recruiting |
| Northwell Health Inc. | Manhasset | New York | 11030 | Recruiting |
| Next Oncology | Fairfax | Virginia | 22031 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
Recently updated Cancer, Breast trials
Other public records listing Cancer, Breast. Sorted by last update posted; newest first. Not a recommendation.
- NCT06268665: Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Recruiting
- NCT05721976: With Love, Grandma ("Con Cariño, Abuelita") Pilot Study Recruiting
- NCT04258813: Onco-primary Care Networking to Support TEAM-based Care Active, not recruiting
- NCT03615599: Plant-based Diets and Risk of Cancer in the Adventist Health Study-2 Active, not recruiting
- NCT03452774: SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry Recruiting
- NCT03451383: Older Breast Cancer Patients: Risk for Cognitive Decline Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05830097, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2024 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05830097 live on ClinicalTrials.gov.